ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Amurins
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • Exebacase
    • CF-370
    • Gram-negative Lysins
    • Amurins
  • Investors & Media
    • Overview
    • News / Events
    • Presentations
    • Company Information
    • Financial Information
    • Analyst Coverage
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Press Releases

Investors & Media

  • Home
  • Investors & Media
  • News / Events
  • Press Releases
Investors & Media

Investors & Media

  • Overview
  • News / Events
    • Press Releases
    • Media Coverage
    • Events
    • Email Alerts
  • Presentations
  • Company Information
  • Financial Information
  • Analyst Coverage
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

December 20, 2019

ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa

December 18, 2019

ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock

December 17, 2019

ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer

December 10, 2019

ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.

December 9, 2019

ContraFect to Present at the Piper Jaffray 31st Annual Healthcare Conference

November 29, 2019

ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update

November 12, 2019

ContraFect to Present at the World Anti-Microbial Resistance Congress 2019

November 5, 2019

ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA

October 2, 2019

ContraFect to Host Development Update Call and Webcast on October 2, 2019

October 1, 2019

RSS
  • 1
  • 2
  • 3
  • 4
  • Next »
© 2023 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Expanded Access Policy Disclaimer Site Map
LinkedIn Twitter